



News Release

February 10, 2026

Notice of Application for Marketing Approval and Launch of Emergency Contraceptive Pill “LESOERU®72”

Fuji Pharma Co., Ltd. (“Fuji”) announces that it has received marketing approval for the emergency contraceptive drug “LESOERU®72” (pharmaceuticals requiring guidance) on Tuesday, February 10, 2026. Fuji also announces that Alinamin Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; hereinafter “Alinamin”) will commence sales as the distributor starting on Wednesday, March 9, 2026.



With regard to the switch of emergency contraceptive pills to OTC status, deliberations began at the Evaluation and Investigation Committee on Switch OTC Drugs in 2016. The Fifth Basic Plan for Gender Equality, issued in 2020, stated that Japan should “consider allowing access to emergency contraception, without a prescription, for women who have the possibility of unintended pregnancy”. Subsequently, in 2021, the Evaluation and Review Committee began to study the switch to OTC use. As part of a government specially approved clinical research program, trial sales of emergency contraceptive pill (morning-after pill) began at selected pharmacies in 2023. In August 2025, the Pharmaceutical Affairs Council of the Ministry of Health, Labour and Welfare approved the switch of emergency contraceptive pills to OTC status.

The emergency contraceptive “LEVONORGESTREL tablet 1.5mg ‘F’”, which Fuji sells as an ethical drug, has a domestic market share of approximately 90% and is prescribed in many clinical environment. Emergency contraceptive pills “LESOERU®72” is a switch OTC medication derived from “Levonorgestrel Tablets 1.5mg ‘F’”, with no formulation differences between the two.

As a company dedicated to women's well-being, Alinamin will deliver “LESOERU®72” alongside appropriate information, contributing to building a society where everyone can access necessary medications when needed.

Please note that this product is a pharmaceuticals requiring guidance which is sold under the proper guidance of a pharmacist who has completed training on the handling of emergency contraceptive medications (“Trained Pharmacist”). When taking this medication, the Trained Pharmacist will provide you with the necessary information.

About Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd. is a Tokyo Stock Exchange (TSE) listed, Japan-based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products. Since our establishment in 1965, Fuji has promoted corporate philosophy that "We help people lead healthy lives by offering excellent pharmaceuticals." and "Our corporate growth is proportional to our personal growth." Fuji Pharma focuses on women's healthcare with a wide variety of drugs for women's specific diseases, dysmenorrhea, endometriosis, menopausal disorders, Infertility, and contraception. Fuji Pharma is a leading company in women's healthcare and support health of women of all ages.

For further information, please visit our website. <https://www.fuji-pharma.jp/>

About Alinamin Pharmaceutical Co., Ltd.

Alinamin Pharmaceutical Co., Ltd. was established in April 2021 when Takeda Consumer Healthcare Company Limited, a subsidiary of Takeda Pharmaceutical Company Limited's over-the-counter pharmaceutical division, became independent and changed its name. The company manufactures and sells pharmaceuticals, quasi-drugs, and other products, including ALINAMIN® and BENZABLOCK®.

Under the corporate message “Innovating GENKI for Tomorrow” the Alinamin is committed to contributing to people's health by providing high-quality, superior products and services along with appropriate information.

For further information, please visit our website. <https://alinamin-pharma.co.jp/en/>

For further information, contact**Fuji Pharma Co., Ltd.**

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

E-mail: fsks@fuji-pharma.jp

Alinamin Pharmaceutical Co., Ltd.

Corporate Communications

E-mail: smb.cc@alinamin-pharma.com